Evidence map›Paper›PMID 39853823›Full record

ReviewYeast (Chichester, England)2024

The Viral K1 Killer Yeast System: Toxicity, Immunity, and Resistance.

Angelina Chan, Michelle Hays, Gavin Sherlock

Abstract readReview
In one paragraph

Review in Yeast (Chichester, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. ThemBio · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Angelina ChanDepartment of Genetics, Stanford University, Stanford, California, USA.
Michelle HaysDepartment of Genetics, Stanford University, Stanford, California, USA.ORCID 0000-0002-8540-3516
Gavin SherlockDepartment of Genetics, Stanford University, Stanford, California, USA.ORCID 0000-0002-1692-4983

Funding

Multisizer 4e - equipment for "Fitness Effects of Beneficial Mutations"R35GM131824 · NIGMS · STANFORD UNIVERSITY · PI Gavin J Sherlock · 2019 to 2026
$3.6M
NIGMS NIH HHS R35 GM131824This study was funded by the Howard Hughes Medical Institute (Grant GT15996), the National Institutes of Health, the National Institute of General Medical Sciences (Grant R35 GM131824).
6 · The paper itself

Abstract

Killer yeasts, such as the K1 killer strain of S. cerevisiae, express a secreted anti-competitive toxin whose production and propagation require the presence of two vertically-transmitted dsRNA viruses. In sensitive cells lacking killer virus infection, toxin binding to the cell wall results in ion pore formation, disruption of osmotic homeostasis, and cell death. However, the exact mechanism(s) of K1 toxin killing activity, how killer yeasts are immune to their own toxin, and which factors could influence adaptation and resistance to K1 toxin within formerly sensitive populations are still unknown. Here, we describe the state of knowledge about K1 killer toxin, including current models of toxin processing and killing activity, and a summary of known modifiers of K1 toxin immunity and resistance. In addition, we discuss two key signaling pathways, HOG (high osmolarity glycerol) and CWI (cell wall integrity), whose involvement in an adaptive response to K1 killer toxin in sensitive cells has been previously documented but requires further study. As both host-virus and sensitive-killer competition have been documented in killer systems like K1, further characterization of K1 killer yeasts may provide a useful model system for study of both intracellular genetic conflict and counter-adaptation between competing sensitive and killer populations.

Indexed as

Killer Factors, YeastRNA VirusesSaccharomyces cerevisiaeCell WallSignal TransductionK1 killer toxinKiller Factors, Yeastcell wall integrityHOG pathwaykiller toxin resistancetotivirus

Identifiers

PMID39853823
PMCPMC11849699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.